EN DE
STOCK COMPARISON

Aarti Drugs vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Aarti Drugs (AARTIDRUGS) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 13, 2026.

As of Aug 13, 2026, Fair Value Calculator sees Aarti Drugs as the less overvalued of the two: Aarti Drugs trades at ₹432 versus a fair value of ₹285 (-34%), while Jiangsu Hengrui Medicine Co trades at ¥54.36 versus ¥25.94 (-52%).
Aarti Drugs
AARTIDRUGS.NSE · INR · Health Care
-34%
upside to fair value
overvalued
Price₹432
Fair Value₹285
Quality54/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-52%
upside to fair value
overvalued
Price¥54.36
Fair Value¥25.94
Quality66/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Aarti DrugsJiangsu Hengrui Medicine Co
Valuation
17.5×P/E (TTM)43.6×
1.33×P/S (TTM)10.84×
2.20×P/B5.76×
11.7×EV/EBITDA33.0×
—PEG0.93×
0.5%Dividend yield0.4%
₹2.00Dividend per share¥0.20
Profitability
8%Net margin25%
11%Operating margin32%
13%Return on equity15%
6%Return on assets9%
Growth
6%Revenue growth (YoY)13%
-1.9%Avg. growth/yr (3Y)13.9%
3.5%Avg. growth/yr (5Y)2.5%
Balance & size
0.17×Debt / equity—
$358MMarket cap$52B
expensiveGrowth qualityhealthy

Even match: 6 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Aarti Drugsof which business quality 53 · market factors 52 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 47
ProfitabilityMargins and returns on capital today
51
63
Quality GrowthAre margins and returns improving?
38
41
CashflowEarnings quality: real cash, not paper profit
26
82
Fin. StrengthBalance sheet, leverage, solvency risk
62
100
InvestmentDisciplined investing over empire-building
67
27
Low VolatilityCalm price path (market factor)
81
78
MomentumPrice trend over the last 3–12 months (market factor)
43
37
52W MomentumDistance to the 52-week high (market factor)
34
30
Net IssuanceBuybacks instead of dilution
86
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Aarti Drugs

DCF Models₹315
Earnings-Based₹223
Dividend Discount₹35.03
Multiples₹394
Asset-Based₹114
Growth DCF₹193
Economic Profit₹244
Growth Earnings₹374

23 of 26 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.78
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥23.65
Asset-Based¥6.44
Growth DCF¥39.88
Economic Profit¥18.21
Growth Earnings¥30.99

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Aarti Drugs
Bear ₹152Fair Value ₹285Bull ₹492
₹432 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥54.36 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Aarti Drugs · Health Care

Quality score54 · above median
Fair value upside-34% · below median

Jiangsu Hengrui Medicine Co · Health Care

Quality score66 · Top 25%
Fair value upside-52% · below median

Bottom line

As of Aug 13, 2026, Fair Value Calculator sees Aarti Drugs as the less overvalued of the two: Aarti Drugs trades at ₹432 versus a fair value of ₹285 (-34%), while Jiangsu Hengrui Medicine Co trades at ¥54.36 versus ¥25.94 (-52%).

Jiangsu Hengrui Medicine Co has the higher quality score (66/100).

See the full analysis →
Aarti Drugs · Jiangsu Hengrui Medicine Co

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Aarti Drugs

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Jiangsu Hengrui Medicine Co

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.